RLAY is trading 4% down at $18.95 as the stock sees profit-taking and digestion following a sharp multi-week rally driven by positive clinical data and a large underwritten equity offering.
- The decline appears to be a cooling-off period after recent capital-raising activities, with no fresh company-specific news released today.
- Today's move is considered idiosyncratic rather than macro-driven, as the broader markets are trading higher while the stock retraces.